The short answer
VK2735 is a dual agonist of the GIP and GLP-1 receptors, the same receptor pair tirzepatide engages. Bays and colleagues published the Phase 2 randomised VENTURE study of weekly subcutaneous VK2735 over 13 weeks in Obesity in March 2026.
Key facts
- Class
- GIP/GLP-1 receptor dual agonist
- Administration
- Weekly subcutaneous
- Trial
- VENTURE, Phase 2, randomised
- Duration
- 13 weeks
- Published
- Obesity, March 2026 (PMID 41508550)
- Same targets as
- Tirzepatide
- Authorisation
- None (investigational)
What it is
A dual agonist engaging both the GIP and GLP-1 receptors. The combination tirzepatide established. Entering a mechanism another compound has already validated is a different proposition from opening a new one: the biology is settled, and the question becomes whether this molecule does it better, more tolerably, or more cheaply.
Why 13 weeks is short, and why that is appropriate
Phase 3 obesity trials run 68 to 80 weeks because weight reduction continues accumulating over that period. Thirteen weeks cannot capture a plateau. It can establish whether the compound is tolerated, whether it produces the expected direction and rough magnitude of effect, and whether to commit to a much larger programme, which is what Phase 2 is for.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
How to read an early figure against a late one
Weight reduction curves have not flattened at three months. A 13-week figure compared against tirzepatide's 72-week result understates the shorter trial, and comparing them directly is the cross-trial error this site keeps returning to. Duration is one of the variables that must match before two numbers mean the same thing.
Why a second GIP/GLP-1 agonist is worth developing
A validated mechanism removes the largest risk in drug development. That the target does not work. What remains is molecular: potency ratio between the two receptors, half-life, tolerability profile, manufacturing cost. Those are real differences, and they are where a second entrant either finds a position or does not.
What Phase 2 does not establish
Durability, cardiovascular or other outcome benefit, or performance against an active comparator. Almost every compound in this class has looked promising at Phase 2. The site has already documented what happens next, programmes withdrawn, non-inferiority missed, hepatic signals emerging,and Phase 3 is where those appear.
Regulatory position
VK2735 holds no marketing authorisation from the MHRA, EMA or FDA and is available only within registered clinical trials. Nothing supplied on this site is related to it or is an alternative to any licensed weight-management medicine.
Frequently asked questions
What does VK2735 target?
The GIP and GLP-1 receptors, the same pair as tirzepatide.
How long did the Phase 2 run?
Thirteen weeks, in the randomised VENTURE study published in Obesity in March 2026.
Can its result be compared with tirzepatide's?
Not directly. Weight curves have not flattened at 13 weeks, so comparing against a 72-week figure understates the shorter trial.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBays HE et al., Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity 2026 (PMID 41508550)pubmed.ncbi.nlm.nih.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
- PubMedThe Paradox and Future of GLP-1/GIP Combination Therapies. Annu Rev Nutr 2026 (PMID 42166683)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- A GLP-1/Glucagon Dual Aimed at the LiverPemvidutide pairs GLP-1 with glucagon receptor agonism and was studied for 24 weeks in metabolic dysfunction-associated steatotic liver disease.
- An Amylin Analogue Built to Stand AlonePetrelintide is described as a potent, stable, long-acting human amylin analogue - engineered by Zealand Pharma with Boehringer Ingelheim.
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.
- The Class's Defining Safety PropertyGLP-1 amplifies insulin secretion only when glucose is already elevated. Below that threshold the signal does almost nothing - which is the whole point.
- Forcing the Channel Shut Regardless of GlucoseSulfonylureas close the beta cell's potassium channel directly, bypassing the glucose sensing step. That is precisely why they cause hypoglycaemia.